The CDC has declared antimicrobial resistance a serious health threat and the World Health Organization states that “antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi."1
Many initiatives have been launched to combat this threat, most notably a 2014 U.S. Executive Order, which emphasizes the importance of addressing the threat of antimicrobial resistance.3 In 2015, the U.S. released a National Action Plan for Combating Antibiotic Resistant Bacteria with a goal for every U.S. hospital to have an Antimicrobial Stewardship Program by the year 2020.4 Antimicrobial resistance, however, continues to grow and complicate patient management.
The T2Direct Diagnostics™ is a major advance toward helping improve stewardship by expediting access to accurate patient data to aid in the decision-making process.
Rapid negative T2 test results lead to a reduction in the use of unnecessary antimicrobials
Eliminating unnecessary drugs and the overtreatment of patients reduces hospital-wide resistance. Current hospital users have shown a reduction in the use of antimicrobial drugs in approximately 75% of patients with a negative test result5 – and this cost savings typically more than covers the cost of the full T2 investment. Implementing T2Direct Diagnostics for suspected sepsis patients can also improve hospital quality metrics through higher hospital ratings and reduced risk of penalties.
“Henry Ford’s use of the T2Candida assay to significantly reduce time to appropriate antifungal therapy is an important advance in rapid diagnostics, patient care, and antifungal stewardship.”
“With the T2Direct Diagnostics, our hospital is not only reducing the use of antifungal therapy, we’re also identifying far more infected patients than was possible with blood culture.”
Watch the impact of T2Direct Diagnostics on stewardship at Huntsville Hospital.
Request a T2Direct Diagnostics meeting.